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Abstract
Evidence that enables us to identify, assess, and access the small airways in asthma and chronic obstructive
pulmonary disease (COPD) has led INTERASMA (Global Asthma Association) and WAO to take a position on the role
of the small airways in these diseases.
Starting from an extensive literature review, both organizations developed, discussed, and approved the manifesto,
which was subsequently approved and endorsed by the chairs of ARIA and GA2LEN. The manifesto describes the
evidence gathered to date and defines and proposes issues on small airway involvement and management in asthma
and COPD with the aim of challenging assumptions, fostering commitment, and bringing about change.
The small airways (defined as those with an internal diameter <2 mm) are involved in the pathogenesis of asthma and
COPD and are the major determinant of airflow obstruction in these diseases. Various tests are available for the
assessment of the small airways, and their results must be integrated to confirm a diagnosis of small airway dysfunction.
In asthma and COPD, the small airways play a key role in attempts to achieve disease control and better outcomes.
Small-particle inhaled formulations (defined as those that, owing to their size [usually <2 μm], ensure more extensive
deposition in the lung periphery than large molecules) have proved beneficial in patients with asthma and COPD,
especially those in whom small airway involvement is predominant.
Functional and biological tools capable of accurately assessing the lung periphery and more intensive use of currently
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available tools are necessary. In patients with suspected COPD or asthma, small airway involvement must be assessed
using currently available tools. In patients with subotpimal disease control and/or functional or biological signs of disease
activity, the role of small airway involvement should be assessed and treatment tailored. Therefore, the choice between
large- and small-particle inhaled formulations must reflect the physician’s considerations of disease features, phenotype,
and response to previous therapy.
This article is being co-published in Asthma Research and Practice and the World Allergy Organization Journal.
Background
A manifesto, from the Latin “manifestum” (meaning
clear or evident), is a declaration of the beliefs, opinions,
motives, and intentions of the issuer, be it an individual
or a group. It is normally based on previously published
opinion or public consensus and attempts to promote
new ideas with prescriptive notions. In the context of
health care, a manifesto describes confirmed evidence,
actions required, and investigations necessary and is is-
sued by a group of experts or a scientific organization
on a specific topic. By leading people to evaluate the gap
between these principles and their current reality, the
manifesto challenges assumptions, fosters commitment,
and provokes change.
The involvement of the small airways of the lung
(“silent zone”) in the pathogenesis of asthma and chronic
obstructive pulmonary disease (COPD) is currently the
object of much research and debate, and the ability to
identify, assess, and access the small airways enables us
to take a position on this timely issue in the light of
available evidence.
We performed a PubMed search using the MeSH
terms “small airway” and “small particle” within the
last 3 years (January 2013 to January 2016). We also
used the key words “large”, “fine”, “small”, “respir-
able”, “extra-fine”, “extra-small particle”, together with
the MeSh terms “asthma/COPD”, which were limited
to clinical trials without time limits. All selected pa-
pers were initially evaluated by a panel of experts to
assess their eligibility in contributing to the state-
ments of the manifesto. In February 2016, the draft
of the manifesto was circulated among the Board of
Officers of Interasma (Global Asthma Association)
and the WAO Board of Directors, who appraised, dis-
cussed, and approved the final version. The final ver-
sion of the Manifesto was approved and endorsed by
the chairs of ARIA and GA2LEN.
We define
Small airways as those with an internal diameter
<2 μm [1].
Drug particles smaller than 5 μm are called “large
particles”; “small particles” are defined as particles whose
size (usually <2 μm) enables them to be depositied in
the lung periphery in greater amounts than large mole-
cules [2–6].
We know
That while the small airways contribute little to total
airway resistance in healthy lungs, in asthma and in
COPD they are the major determinant of airflow ob-
struction [7, 8].
It has been estimated that 75 % of the small airways
must be obstructed before changes can be detected
using routine pulmonary function tests (e.g. forced ex-
piratory volume in 1 s [FEV1]) [9].
Various tests are available for the assessment of small
airways. The detection of an abnormal forced expiratory
flow (FEF25–75) should be supported by other pulmonary
function tests (impulse oscillometry, whole-body pleth-
ysmography, exhaled-breath nitric oxide, and single-
breath and multiple-breath nitrogen washout) to con-
firm a diagnosis of small airway dysfunction [4, 10–12].
Asthma
The small airways play a role in the pathobiology of
asthma and, although they are involved in half of all
cases of asthma, they can have a distinct role in specific
disease phenotypes [13–17].
Inflammatory changes involving the small airways
influence the severity of asthma [18–23].
Functional alterations of the small airways are also
associated with the severity of asthma [24–32].
The role of the small airways in asthma is increasingly
recognized as a potential target in optimal control of the
disease [33–36].
The development of small-particle inhaled formula-
tions enables the drug to reach both the large and the
small airways [37–39].
Small-particle aerosols have been shown to be as ef-
ficacious as large-particle aerosols in randomized con-
trolled trials; however, real-life studies have shown
that smaller particles are more efficacious and im-
prove asthma control and quality of life compared
with large particles; in addition, they do so with a
marked reduction in the daily dose of inhaled cortico-
steroids (ICS) [37, 40–75].
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COPD
COPD is characterized by a mixture of small airway im-
pairment (obstructive bronchitis/bronchiolitis) and par-
enchymal lung tissue destruction (emphysema). The
progression of COPD is strongly associated with small
airway wall thickening as a result of lung repair or re-
modelling [76–79].
Small airway disease in COPD can be identified by
pulmonary function testing, multiple nitrogen breath
washout testing, indirectly through high-resolution chest
computed tomography (CT) imaging or inert-gas MRI
imaging, or directly using microCT of resected lung
tissue [80, 81].
In COPD, air trapping and functional small airway im-
pairment are associated with inflammation of the per-
ipheral airways [82–84].
The effects of significantly low-dose small-particle ICS
on exacerbation rates are similar to those of larger-
particle ICS at higher doses. Initiation of small-particle
ICS is associated with a greater likelihood of stable treat-
ment [85–87].
The combination of small-particle ICS and long-acting
beta-agonists has been effective in reducing air trapping
and improving health-related quality of life and dyspnea
in COPD patients with lung hyperinflation [88–94].
We state
That small airways play a key role in the pathogenesis of
asthma and COPD.
In asthma and in COPD, the small airways can be tar-
geted to ensure disease control and better outcomes.
Small-particle inhaled formulations are beneficial in
patients with asthma and COPD, especially those with
predominant small airway involvement.
We advocate
The need for functional and biological tools that can ac-
curately assess the lung periphery and a more intensive
use of currently available tools for improved patient
phenotyping.
The lack of consensus on the terminology used to de-
scribe small drug particles necessitates a clear nomencla-
ture to ensure that uniform terminology is used by
professionals.
Research should aim to identify a specific “small air-
way phenotype” so that uncontrolled disease can be
treated appropriately.
We propose
That in patients with suspected COPD or asthma, small
airway involvement should be taken into consideration
and explored using currently available tools.
In patients with suboptimal disease control and/or
functional or biological signs of disease activity, the role
of the small airways should be assessed to provide tai-
lored treatment.
The choice of large-particle inhaled formulations over
small-particle inhaled formulations must reflect the
physician’s considerations of disease features, phenotype,
and response to previous therapy.
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